Assessment of Mechanisms Involved in Antinociception Caused by Myrsinoic Acid B

DOI Web Site Web Site 被引用文献1件 参考文献44件
  • Hess Sarai
    Centro de Ciências da Saúde/Programa de Mestrado em Ciências Farmacêuticas, Universidade do Vale do Itajaí
  • Padoani Cristina
    Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí
  • Scorteganha Laiana Carla
    Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí
  • Holzmann Iandra
    Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí
  • Malheiros Angela
    Centro de Ciências da Saúde/Programa de Mestrado em Ciências Farmacêuticas, Universidade do Vale do Itajaí Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí
  • Yunes Rosendo Augusto
    Departamento de Química, Universidade Federal de Santa Catarina, Campus Universitário Trindade
  • Delle Monache Franco
    Istituto di Chimica, Università Cattolica
  • de Souza Márcia Maria
    Centro de Ciências da Saúde/Programa de Mestrado em Ciências Farmacêuticas, Universidade do Vale do Itajaí Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí

この論文をさがす

抄録

Myrsinoic acid B (AMB) is a prenylated-benzoic acid derivative isolated from the Rapanea genus. Recent studies suggest that AMB has antihyperalgesic and antinociceptive properties in different animal models. The present study was designed to investigate the mechanisms involved in antinociception elicited by AMB (60 mg/kg) when administered by intraperitonial route (i.p.) in mice. The antinociceptive response of the compound was characterized by a reduction in contractions of the abdominal muscle, together with stretching of the hind limbs in response to i.p. injection of acetic acid (0.6%, 0.45 ml/mouse). The antinociception caused by AMB in the acetic acid test was significantly attenuated by i.p. treatment of mice with nitric oxide precursor, (L-arginine, 600 mg/kg), α2 and α1-adrenoceptor antagonists (yohimbine, 0.2 mg/kg/prazosin, 0.2 mg/kg), p-chlorophenylalanine (PCPA) an inhibitor of serotonin synthesis (100 mg/kg), 1-(2-methoxyphenyl)-4-(4-phthalimidobutyl)piperazine (NAN 190), a 5-HT1A selective receptor antagonist (0.5 mg/kg) and a non-selective cholinergic antagonist (atropine, 10 mg/kg). Its action was also modulated by the adrenal-gland hormones. In contrast, antinociception was not affected by naloxone (non-selective opioid receptor antagonist, 1.0 mg/kg), phaclofen (2.0 mg/kg) and bicuculline (1.0 mg/kg) GABAB and GABAA receptor antagonists, respectively, ondansetron (0.3 mg/kg) and ketaserin (1.0 mg/kg), (5-HT3 and 5-HT2 receptors, respectively) and haloperidol (0.2 mg/kg), a non-selective dopaminergic receptor. The antinociceptive effects are not related to muscle-relaxant or sedative action. These results indicate that AMB produces antinociception through mechanisms that involve interaction with L-arginine–nitric oxide, the serotonergic and cholinergic systems, as well as interaction with the α-adrenoceptors.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (44)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ